close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

36.58 -1.68 (-4.39%)
Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors
From UroGen Pharma Ltd.
Via Business Wire
News headline image
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation
From UroGen Pharma Ltd.
Via Business Wire
News headline image
Recap: UroGen Pharma Q1 Earnings ↗
 
Via Benzinga
News headline image
UroGen Pharma Earnings Preview ↗
 
Via Benzinga
UroGen Pharma's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
UroGen Pharma to Host UGN-102 Data Event on July 27, 2023
From UroGen Pharma Ltd.
Via Business Wire
News headline image
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
News headline image
Earnings Scheduled For May 11, 2023 ↗
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... 
Via Benzinga
News headline image
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023
From UroGen Pharma Ltd.
Via Business Wire
News headline image
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation
From UroGen Pharma Ltd.
Via Business Wire
News headline image
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
From UroGen Pharma Ltd.
Via Business Wire
News headline image
Earnings Scheduled For March 16, 2023 ↗
Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million. 
Via Benzinga
News headline image
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
News headline image
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023 ↗
 
Via Benzinga
News headline image
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma
From UroGen Pharma Ltd.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.